News

FDA clears drug for leading form of cystic fibrosis

FDA clears drug for leading form of cystic fibrosis

Source: The Seattle Times

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will come at a steep price — more than $250,000 for a year’s treatment. Two large Phase 3 clinical trials confirming the drug’s effectiveness were co-led by Dr. Bonnie Ramsey, a professor of pediatrics at the University of Washington School of Medicine and the Center for Clinical and Translational Research at Seattle Children’s Research Institute. About 25 Washington state patients participated in the trials.

About Seattle Children’s Research Institute

Located in downtown Seattle’s biotech corridor, Seattle Children’s Research Institute is pushing the boundaries of medical research to find cures for pediatric diseases and improve outcomes for children all over the world. Internationally recognized investigators and staff at the research institute are advancing new discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics, among others. As part of Seattle Children’s Hospital, the research institute brings together leading minds in pediatric research to provide patients with the best care possible. Seattle Children’s serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. For more information, visit http://www.seattlechildrens.org/research.